Title: Detection of a Tertiary Pattern of Higher Grade in Core Biopsy Tissues of Prostatic Adenocarcinoma– A Case Report

Authors: Ashok Kumar Kapoor, Mustafa Ali, Yamini Jindal

 DOI:  https://dx.doi.org/10.18535/jmscr/v4i10.101

Abstract

ABSTRACT

Present study relates with the results of histopathological examination of core biopsy tissue from a patient with prostatic adenocarcinoma.  Adenocarcinoma was graded according to Gleason’s criteria into 5 grades (grade 1 to 5) with decreasing differentiation.  Histopathological classification of tumour mainly depends upon architectural irregularities with increasing anaplasia.  At least 2 patterns are recognized in a prostatic carcinoma.  In addition, most prevalent grade is added with second most common grade to obtain a Gleason score.

KEY WORDS: Adenocarcinoma Prostate Gleason tertiary pattern

References

1.      Humphrey PA.  Gleason grading and pron-gostic factors in carcinoma of the prostate.  Modern Pathol 2004; 17:292-306.

2.      Kir G, Senelder H, Gumus E.  Outcomes of gleason score 3+4 = 7 prostate cancer with minimal amounts (< 6%) Vs > 6% of Gleason pattern 4 tissues in needle biopsy specimens.  Ann DiagnPathol 2015; 20:48-51.

3.      Montironi R, Mazzucheli R, Scarpelli M, Lopez-Beltran A, Fellegara G, Algaba F.  Gleason grading of prostate cancer in needle biopsies or radical prostatectomy specimens contemporary approach, Current clinical significance and sources of pathology discrepancies.  BJU international 2005; 95:1146-1152 (doi:10.1111/J.1464-410 x 2005.05540 x).

4.      Hashima K, Yuasa A, Sinomori K, Shirato A, Ninomiya I, Teramoto N.  Tertiary Gleason pattern 5 and oncological outcomes after radical prostatectomy.  Japanese J ClinOncol 2011; 41:571-576.

5.      Koloff ZB, Hamstra DA, Wei JT, Montgomery JS et al.  Impact of tertiary Gleason pattern 5 on prostate cancer aggressiveness: Lessons from a contemporary single institution radical prostatectomy series.  Asian J Urol 2015; 2:53-58.

6.      Greenberg PD, Mechanisms of tumour immunology.  In Parslow TG, Slites DP, Terr AI, Imboden JB eds.  Medical immunology 10thed.  New York: Lange medical books / McGraw-Hill publishing division: 2001, p568-571.

7.      Montie JE, Wood DP, Ponter JE, Boyett JM, Levin HS.  Adenocarcinoma of the prostate in cystoprostatectomy specimens removed for bladder cancer.  Cancer 1989l 63:381-385.

8.      Ismar TA, Lewis JS jr, Vollmer RT, Humphrey PA.  Multiple measures of carcinoma extent versus perineural invasion in prostatic needle biopsy tissue in prediction of pathologic stage in a screening population.  Amer J SurgPathol 2003; 27:432-440.

9.      Damjanov I, McCue PA.  In situ and invasive adenocarcinoma of the prostate.  In Rubin’s Pathology, 7th ed. Strayer DS, Rubin E, Saffiz JE and Schiller AL 2015; Philadelphia : Wolters Kluwer p990-994.

10.  Kim HL, Yang XJ.  Prevalence of high-grade intraepithelial neoplasia and its relationship to serum prostate specific antigen.  IntBraz J Urol 2002; 28:413-417.

Corresponding Author

Ashok Kumar Kapoor